- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 495/08 - Bridged systems
Patent holdings for IPC class C07D 495/08
Total number of patents in this class: 90
10-year publication summary
|
9
|
2
|
8
|
5
|
10
|
2
|
3
|
2
|
5
|
3
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme LLC | 3732 |
7 |
| Genentech, Inc. | 4016 |
5 |
| Universitat Rovira I Virgili | 105 |
4 |
| Bristol-myers Squibb Company | 4826 |
3 |
| Georgia Tech Research Corporation | 2831 |
3 |
| Alnylam Pharmaceuticals, Inc. | 1140 |
3 |
| Fundació Institut Català D'investigació Química (iciq) | 47 |
3 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2915 |
3 |
| Sanofi | 4140 |
3 |
| Merck Sharp & Dohme Corp. | 2189 |
2 |
| Janssen Pharmaceutica N.V. | 3358 |
2 |
| Merck Patent GmbH | 5752 |
2 |
| Astellas Pharma Inc. | 1057 |
2 |
| Eli Lilly and Company | 3926 |
2 |
| The Global Alliance for TB Drug Development, Inc. | 42 |
2 |
| Schering Corporation | 413 |
2 |
| Tokyo Ohka Kogyo Co., Ltd. | 1547 |
2 |
| HTG Molecular Diagnostics, Inc. | 37 |
2 |
| USA Elixiria Biotech Inc | 3 |
2 |
| Awakn LS Europe Holdings Limited | 14 |
2 |
| Other owners | 34 |